SCHEMBL1638470

SCHEMBL1638470

COc1ccc(/C=N\NC(=O)c2ccccc2O)c(O)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 2/20 0.74
KDM4E B2RXH2 5/20 0.67
MGAM O43451 3/20 0.67
MEN1 O00255 3/20 0.67
KMT2A Q03164 3/20 0.67
TDP1 Q9NUW8 2/20 0.67
GAA P10253 2/20 0.67
SI P14410 2/20 0.67
MGAM2 Q2M2H8 2/20 0.67
TP53 P04637 1/20 0.67
CYP3A4 P08684 1/20 0.67
CYP2D6 P10635 1/20 0.67
HPGD P15428 1/20 0.67
MAPK1 P28482 1/20 0.67
HSD17B10 Q99714 1/20 0.67
NPSR1 Q6W5P4 2/20 0.60
MAPT P10636 3/20 0.59
POLB P06746 2/20 0.59
HTT P42858 1/20 0.59
RECQL P46063 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12766734 1.00 NTRK1 (0.74) NTRK1KDM4EMGAMMEN1KMT2A
SCHEMBL1638472 1.00 NTRK1 (0.74) NTRK1KDM4EMGAMMEN1KMT2A
SCHEMBL17832045 0.90 MGAM (0.64) NTRK1KDM4EMGAMMEN1KMT2A
SCHEMBL13972137 0.90 NTRK1 (0.60) NTRK1KDM4EMGAMMEN1KMT2A
SCHEMBL12746275 0.90 MGAM (0.64) NTRK1KDM4EMGAMMEN1KMT2A
SCHEMBL1639490 0.90 MGAM (0.67) NTRK1KDM4EMGAMMEN1KMT2A
SCHEMBL1639491 0.90 MGAM (0.67) NTRK1KDM4EMGAMMEN1KMT2A
SCHEMBL12767328 0.90 MGAM (0.67) NTRK1KDM4EMGAMMEN1KMT2A
SCHEMBL12746305 0.89 GUSB (0.66) NTRK1KDM4EMGAMMEN1KMT2A
SCHEMBL13972162 0.88 KDM4E (0.60) NTRK1KDM4EMGAMMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US claimed
EP-2194975-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS Acumen Pharmaceuticals, Inc. (US) 2010-06-16 EP claimed
WO-2009009768-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS ACUMEN PHARMACEUTICALS, INC. (US) 2009-01-15 WO claimed
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
EP-2194975-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS Acumen Pharmaceuticals, Inc. (US) 2010-06-16 EP disclosed
WO-2009009768-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS ACUMEN PHARMACEUTICALS, INC. (US) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS APP, APBA1, BACE1 NTRK1 1503/4885KDM4E 4638/4885MGAM 1174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.